Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Supernus Pharmaceuticals ( (SUPN) ) has shared an update.
On May 17, 2026, Supernus Pharmaceuticals notified its rights agent that Milestone 1 under its Contingent Value Right Agreement, originally executed on July 30, 2025, had been achieved on March 18, 2026. As a result, the company is obligated to make a milestone payment of $0.50 per Contingent Value Right, totaling approximately $33.4 million in cash, subject to applicable withholding taxes.
Supernus plans to deposit the funds with the rights agent within 20 business days of the notice date, with distributions to CVR holders to follow under the agreement’s terms. The payment underscores progress on conditions tied to the CVRs, signaling the company’s advancement against previously defined performance targets and delivering a direct cash benefit to holders of these contingent securities.
The most recent analyst rating on (SUPN) stock is a Buy with a $66.00 price target. To see the full list of analyst forecasts on Supernus Pharmaceuticals stock, see the SUPN Stock Forecast page.
Spark’s Take on SUPN Stock
According to Spark, TipRanks’ AI Analyst, SUPN is a Neutral.
SUPN scores solidly on financial strength and liquidity (low leverage, strong cash/FCF) and the earnings call reinforced improving operating trends with reiterated 2026 guidance and strong YoY revenue growth. The main offsets are recent GAAP losses (driving a negative P/E and weaker valuation signals) and execution risks around elevated operating expenses and supply/regulatory timing for Onepco.
To see Spark’s full report on SUPN stock, click here.
More about Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies, particularly in neurology and related central nervous system disorders. The company operates in the U.S. market and leverages proprietary technologies and product candidates to address unmet medical needs in its chosen therapeutic areas.
Average Trading Volume: 719,966
Technical Sentiment Signal: Buy
Current Market Cap: $2.81B
For a thorough assessment of SUPN stock, go to TipRanks’ Stock Analysis page.